Loading...
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Chapman, P Robert, C Larkin, J Haanen, J Ribas, A Hogg, D Hamid, O Ascierto, P Testori, A
Chapman, P
Robert, C
Larkin, J
Haanen, J
Ribas, A
Hogg, D
Hamid, O
Ascierto, P
Testori, A
Citations
Altmetric:
Abstract
The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with BRAFV600 mutation-positive metastatic melanoma. We present final OS data from BRIM-3.
Description
Date
2017-10-01
Publisher
Collections
Files
Keywords
Type
Article
Citation
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. 2017, 28 (10):2581-2587 Ann Oncol